Analysts identify ASX fallen angels like Aurora, Ramsey Health Care, and SiteMinder as potential turnarounds based on balance sheet fixes and management changes.
Summary
Matt Riordan and Marcus Burns discuss criteria for identifying genuine stock turnarounds versus value traps on the ASX. They analyze Aurora Limited (AUR), noting its core business trades cheaply while Savourglass faces headwinds. Ramsey Health Care (RHC) is highlighted for new leadership and a demerger plan to de-leverage. IDP Education (IOD) is held despite political risks due to low valuation. SiteMinder (SMT) and Cochlear (COH) are picked for cash flow recovery and product innovation respectively.
Episode sections
- 0:00 – 1:07
Intro and Sponsor Read
James Marley introduces the LiveWire Live event.
- 1:07 – 2:46
Defining Turnaround Criteria
Riordan and Burns discuss distinguishing turnarounds from value traps based on structural vs cyclical factors and balance sheet health.
- 2:46 – 5:35
Aurora Limited (AUR) Analysis
Discussion on Aurora's diversified businesses, with Riordan holding and Burns buying based on low valuation of the core business.
- 5:35 – 7:51
Ramsey Health Care (RHC) Analysis
Burns holds and Riordan buys RHC, citing new CEO, improved health fund deals, and value unlock from demerging Ramsey Santé.
- 7:51 – 9:47
IDP Education (IOD) Analysis
Both guests hold IOD despite political headwinds, citing low valuation (8-9x EBIT) and strong balance sheet.
- 9:47 – 11:25
Guest Pick: SiteMinder (SMT)
Burns picks SMT, arguing the market overreacted to growth guidance cuts despite cash flow profitability.
- 11:25 – 13:28
Guest Pick: Cochlear Limited (COH)
Riordan picks COH, expecting stabilization in 2026 driven by new products like the Nexa implant.
Claims worth verifying
LiveWire Live is taking place on the 22nd of September at the Art Gallery of New South Wales.
Unidentified speaker (speaker_0) ·0:19
How to verify: Check LiveWire Markets website or event listing for 'LiveWire Live 10th edition' details. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Aurora Limited acquired Savourglass at the end of 2023.
Unidentified speaker (UNKNOWN) ·3:28
How to verify: Check Aurora Limited annual reports or ASX announcements for the Savourglass acquisition date and details. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Aurora's core Australian business trades at approximately 10x EBIT.
Unidentified speaker (speaker_3) ·5:17
How to verify: Calculate Aurora Limited's Enterprise Value/EBIT or P/E ratio using current share price and latest financial statements. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Primary sourceRamsey Health Care is planning to spin off Ramsey Santé.
Unidentified speaker (speaker_2) ·7:26
How to verify: Check Ramsey Health Care ASX announcements or investor presentations regarding corporate restructuring. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Ramsey Santé spin-off will add 8% to earnings per share.
Unidentified speaker (speaker_2) ·7:29
How to verify: Check Ramsey Health Care investor presentations or financial models detailing the expected EPS accretion from the demerger. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
IDP Education trades at 8-9x EBIT.
Unidentified speaker (speaker_3) ·9:23
How to verify: Calculate IDP Education's EV/EBIT or P/E ratio using current share price and latest financial statements. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Primary sourceSiteMinder returned to cash flow profitability in 2026.
Unidentified speaker (speaker_3) ·10:18
How to verify: Check SiteMinder quarterly or annual financial reports for 2026 confirming positive cash flow. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
SiteMinder reduced its revenue growth guidance from 30% to 25%.
Unidentified speaker (speaker_3) ·10:38
How to verify: Check SiteMinder investor presentations or earnings releases detailing guidance changes. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Cochlear Limited introduced a new implant called Nexa.
Unidentified speaker (speaker_2) ·12:13
How to verify: Check Cochlear Limited press releases or product launch announcements for the 'Nexa' implant. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Do your own research
- Verify Aurora Limited's (AUR) latest annual report for Savourglass impairment tests and EBITDA contributions.
- Check Ramsey Health Care's (RHC) latest investor presentation for details on the Ramsey Santé demerger timeline and EPS accretion claims.
- Review IDP Education's (IOD) quarterly reports for student visa cap impacts and cost-cutting execution.
- Confirm SiteMinder's (SMT) 2026 cash flow profitability figures in their latest financial statements.
- Analyze Cochlear Limited's (COH) US/UK reimbursement policy changes and Nexa implant adoption rates.
- Assess the political risk environment for Australian education providers via government policy announcements.
- Check balance sheet leverage ratios for all mentioned companies to verify 'de-gearing' progress.
- Review management commentary for any changes in guidance or strategic direction since the podcast recording.
Full transcriptexpand
- 0:00
- Unidentified speaker (speaker_0): Hey listeners, it's James Marley, co-founder at LiveWire Markets. In 2014 we had an idea. What if we brought Australia's leading investors into one room and put their best ideas on the table? That first event sold out and every year since we've raised the bar. This September, LiveWire Live returns for its milestone 10th
- 0:19
- Unidentified speaker (speaker_0): edition. It's taking place on the 22nd of September at the Art Gallery of New South Wales. Seats are Illimited, limited. head to LiveWire LiveWireMarkets.com Markets.
- 0:27
- Unidentified speaker (speaker_0): to secure yours.
- 0:38
- Unidentified speaker (UNKNOWN): Welcome
- 0:39
- Unidentified speaker (speaker_1): to LiveWire's Buy Hold Sell. My name is Anna Daddic, and today we're tackling the Fallen Angels, stocks that have been And cast from the heavens due to macro tempests, hubris, and trials in the market cycle. Today we are ask whether those fallen idols can rise from the ashes and reclaim their former glory. Joining me to see which companies are on the road to redemption
- 0:59
- Unidentified speaker (speaker_1): are Matt Reedan from Paradise and Marcus Burns from Sferia. Gentlemen, welcome.
- 1:04
- Unidentified speaker (speaker_2): Thank
- 1:04
- Unidentified speaker (UNKNOWN): you.
- 1:05
- Unidentified speaker (speaker_1): Okay, Matt, I'm gonna start with you.
- 1:07
- Unidentified speaker (speaker_2): Yes.
- 1:08
- Unidentified speaker (speaker_1): When a high-profile Profile stock gets heavily beaten down, it often looks cheap on traditional metrics. What is the single biggest filter you use to separate a genuine turmer turnaround from a value trap?
- 1:19
- Unidentified speaker (speaker_2): Great, thanks and I I like the introduction by the way. Thank you. It's always uh problematic. But um that's a great question. And uh like Avio Paradises, just because if a stock falls doesn't necessarily make a good value. You really have to understand what the reasons are, whether those reasons are structural and whether they're cyclical and whether a solution exists. So you
- 1:39
- Unidentified speaker (speaker_2): know, for us it's assessing whether that solution's in place and if if there's essentially a catalyst to see that stock start to perform again.
- 1:46
- Unidentified speaker (speaker_1): Okay. Marcus, once market sentiment turns negative on a company, it can take a long time to recover. So what is a specific operational sign or inflection point that you need to see to gain confidence that a turnaround is actually underway?
- 2:01
- Unidentified speaker (UNKNOWN): Well
- 2:01
- Unidentified speaker (speaker_3): it's that's a that's a million dollar. question in some cases more. But um and look and again there's no single answer for that. I think um uh you know we'll do a number of checks this very we'd be looking for uh things have fallen out of bed, um they've derated. Um often that's because debt's very high or there's been a major missed to earnings or a combination of those two things. So before we got involved we'd like to see
- 2:21
- Unidentified speaker (speaker_3): some kind of control or backstop to balance sheet. sheets. So often there'll be a capital raising or some kind of backstop to kind of underpin the business bit the at a at a at a you know at a certain valuation level, plus dig ear and de-risk the business. And then often a new management team coming in with a solution to what the previous issues and problems were. So that's often a turnaround case for us. Absent those factors, it
- 2:41
- Unidentified speaker (speaker_3): might get cheap enough, but um you know we still need good balance sheets and cash flows for us to be interested in getting involved.
- 2:46
- Unidentified speaker (speaker_1): Yeah, need to see the evidence. Okay, let's get into the stocks. Uh kicking up with off packaging group Aurora, it was hit hard after funding its big acquisition of French luxury glassmaker savourglass. Matt,
- 3:00
- Unidentified speaker (speaker_2): are
- 3:00
- Unidentified speaker (speaker_1): you a buy, hold, or sell?
- 3:01
- Unidentified speaker (speaker_2): A hold. Okay.
- 3:02
- Unidentified speaker (UNKNOWN): Tell us why.
- 3:03
- Unidentified speaker (speaker_2): I'll run you through the reasons. So if you think about Aurora, there's there's three businesses in it. So the first is there's a cans business, so beverage business, and that's a really good business. You know, cans are benefiting. from a move away from plastics. Um, so that that's a good gross business. Second business is Australian Glass, so that includes you know a lot of wine bottles and the like. That's a business that
- 3:23
- Unidentified speaker (speaker_2): had been in decline, they've managed to stabilize that business. And the third business is the one you mentioned, which is Savaglass. So,
- 3:28
- Unidentified speaker (UNKNOWN): you know,
- 3:29
- Unidentified speaker (speaker_2): if you go back, that was an acquisition they did in 2023, at the end of 2023. I guess it's been somewhat controversial, and you you touched on it. So if you look at it, it's got a dual exposure there. So first it's
- 3:42
- Unidentified speaker (speaker_2): alcohol and then it's it's premium. So if you go, they bought it coming out of COVID. It was a big beneficiary during COVID. So you think about, I don't know about you guys, but during COVID, stuck at home, cocktail nights, you stocked up the liquor cabinet. So I think we've all got like a lot of our spirits bottles sitting around from that time. Um, But since then we've run into you know dual issues.
- 4:03
- Unidentified speaker (speaker_2): That the first is that alcohol consumption is decreasing across the population, we see that through a number of industries. And the second is just the premium end is proving quite difficult. And I mean, just you know, look at uh you know, look at the economy over here, you've got you know issues in terms of you know inflation, rates going up globally, so it's put pressure on a lot of people. So for us, what
- 4:22
- Unidentified speaker (speaker_2): we really want to see, and they've obviously done a lot of work around that business, is we we really just want to see that business well first stabilize and then just start to move in an upward trajectory, and I guess sort of prove their acquisition case. So that that's Aurora for us.
- 4:35
- Unidentified speaker (UNKNOWN): Okay. All right, Marcus, what's your
- 4:37
- Unidentified speaker (speaker_3): thought? Well, it's good, you know, buy, sell, hold. We're a buyer of that of that case. And I think Matt's made a good point. The um Saberglass acquisition was probably poorly timed and the price in hindsight was obviously too high. Um but I guess the share price of Aurora has always fallen away. fallen a lot since then. And yeah, Matt's got a point. There's three good three businesses there. The Cannes business is actually in
- 4:56
- Unidentified speaker (speaker_3): structural growth, it seems. There's been a switch towards Cans, they're the leading player in CAN packaging in Australia. It's a good cash flow business, so the cash flow generation is strong across the group. And given the share price has fallen so much, and it is quite cash generative, we think you're probably getting saved saviglass glass for free, basically. If you look at the core business in Australia, you're only paying about 10 times. EBIT for the whole group. Um,
- 5:17
- Unidentified speaker (speaker_3): and so on that basis, we think it's probably a buy.
- 5:19
- Unidentified speaker (speaker_1): Okay, it's always better to drink from a can as well than plus, it just tastes better. Anyway, on to uh private hospital giant Ramsey Healthcare. Um, it was once a king of defensive compounders. Marcus, I'm gonna stay with you. Are the cost pressures too stubborn? Buy, hold, or sell.
- 5:35
- Unidentified speaker (speaker_3): Look, we are we were a buyer of that stock and it's performed really well over. the last six months. Um, but now it would be probably via holder. Um the reason there is it's performed well, a fair bit of recoveries in the share price. Um they've got a troubled uh European operation which is very indebted, very low margin, um, needs some restructuring. They're looking to demerge that
- 5:55
- Unidentified speaker (speaker_3): and leave the core Australian business um separate from that, which would de-gear dig gear the business massively if they were successful in doing that. So, but a fair bit of that that recoveries in the share price. So look, we like it structurally. There's growth there with people aging and the need for hospital care. Um, so we like the business, um, like you know, approved we'd like the D merger to go ahead, but give evaluation and the way it's moved probably hold.
- 6:15
- Unidentified speaker (speaker_1): Sure. Okay, Matt, yeah.
- 6:16
- Unidentified speaker (speaker_2): We're actually we're still a buy. Um, I'd
- 6:19
- Unidentified speaker (UNKNOWN): I
- 6:19
- Unidentified speaker (speaker_2): agree with everything Marcus said. Um, you know, for us it's it's an interesting stock. It used, you know, going back at the early days of that our fund, it was one
- 6:26
- Unidentified speaker (UNKNOWN): of the
- 6:26
- Unidentified speaker (speaker_2): mainstays. It moved up into the top 50 and it's since come back to us, and it ran in. And you touched on Anna, the difficult times it had, you know, inflation was rife, then we went through COVID, um, and then even coming out of COVID, we you know, we saw elective surgeries didn't really come back. And so, fast forward, and um you know, the business has really started to change. I've got a new CEO, um, Natalie
- 6:46
- Unidentified speaker (speaker_2): Davis, who's been absolutely superb. So a couple of things have worked in their favour. First of all, they've made managed to get, you know, new agreements with the health funds where they get more of the pie. And that was one of the bigger issues that they had where the health funds actually were, you know, getting a disproportionate share. But on top of that, you know, we're seeing Natalie's really pushing efficiency through that business. And this
- 7:06
- Unidentified speaker (speaker_2): for us, we still think there's like a lot of efficiency still to come. We think it's only early days in in terms of those coming through. So we think there's a lot of scope for you. margins to improve within Australia. And then the final thing for us, it's quite a complex structure. They over time they bought a couple of overseas businesses. The market doesn't like those as much. They're about to spin off Ramsey Sante,
- 7:26
- Unidentified speaker (speaker_2): and the real benefit of that, that's
- 7:29
- Unidentified speaker (speaker_2): European base. But it actually has a value. It's listed in Europe, so you can see it has a value, but it actually loses money. So that the act of spinning spending that off alone a loan is 8%. of creative. And then you get left on top of that, you know, with an additional holding, which is also worth something. So we so we see an upside caloris as well coming from that that change. So
- 7:48
- Unidentified speaker (speaker_1): all right, moving on to international student placement and language testing heavyweight, IDP education. Once the quintessential market compounder, its share price was chopped by student after student visa caps and migration crackdown. crackdowns. Matt, I'm gonna stay with you. Yeah. Yeah. Hold or sell.
- 8:06
- Unidentified speaker (speaker_2): Hold for us. And I think you've you've summarised it really well. Really good business. Unfortunately, they've run into some significant political headwinds recently. You know, they've got the two businesses the language testing, student placement. Both of those are subject to what's happening in, And you know, in terms of um, I guess sort of the anti anti-migration migration sentiment that we're seeing politically, and you know,
- 8:26
- Unidentified speaker (speaker_2): a very easy way. to cut migration is actually just reducing student numbers. So we think the company's done a really good job to try and manage that. They've cut costs dramatically. They they've they've got really good um, you know, sort of price levers that we see coming through each year. But, you know, for us, um, you know, we sort of sit here, the the that political environment hasn't changed. And I think we'd just
- 8:46
- Unidentified speaker (speaker_2): like to see, you know, things sort of calm down before um you you know we'd look at buying that stock. So Yeah,
- 8:50
- Unidentified speaker (UNKNOWN): of course.
- 8:51
- Unidentified speaker (speaker_1): Okay, Marcus, what about you?
- 8:52
- Unidentified speaker (speaker_3): Well, um fortunately we're the same. We're it would be would be a holder. It's not um like we don't like the business. Uh as Matt said, it's got two two businesses. One was you know particularly good. The um
- 9:02
- Unidentified speaker (UNKNOWN): English
- 9:02
- Unidentified speaker (speaker_3): language testing was a very good, you
- 9:03
- Unidentified speaker (UNKNOWN): know,
- 9:04
- Unidentified speaker (speaker_3): high cash business, quite a strong geopoly globally. Um it's received more competition in the last couple of years, so that the margins and and growth there are under under pressure as well as the pricing to some extent. Um and as Matt said, the political situation hasn't been favourable for student politics and students coming to country. So it is somewhat in the price, it's derated aggressively from a very high multiple, high growth, well loved
- 9:23
- Unidentified speaker (speaker_3): stock to one that's really debased. Um balance sheet's in pretty good shape, it makes good cash flow. Trades on you know eight, nine times eBay, so it's not like you're paying a lot for the business, but I guess you know we are cautious around the medium term because of those those threats.
- 9:37
- Unidentified speaker (speaker_1): Yeah, sure. Too many risks. Okay. uh now onto our guest picks. I've asked our guests to bring along a fallen angel there backing on the ASX. Marcus, what's your fallen angel?
- 9:47
- Unidentified speaker (speaker_3): It's an interesting uh analogy. Fallen Angel. We look, we I would put forward Sighteminder, which is um
- 9:53
- Unidentified speaker (UNKNOWN): a
- 9:53
- Unidentified speaker (speaker_3): technology business that effectively plugs into hotels
- 9:57
- Unidentified speaker (speaker_3): and
- 9:58
- Unidentified speaker (UNKNOWN): if for I
- 9:58
- Unidentified speaker (speaker_3): want of a better term, manages their calendar across different booking channels. It Does more than that, but that's the cool. core core business. It's fallen, you know, it floated back in 2021. It has had four or five years of very strong revenue growth. Admittedly, it was losing money when IPO'd. And it's since reduced losses over time as the revenue's grown. So now it's gone through break-even as making money in
- 10:18
- Unidentified speaker (speaker_3): cash flow this year, the first time since 21. It's got a fairly sticky customer base, so high retention, and it's grown, it's grown its business from the core business into trans. transactions. So it is getting a revenue growth of, you know, call it mid twenty percent. But they haven't really communicated well their sort of their growth targets and they they cut them back from thirty down to twenty-five, which the market saw as a huge
- 10:38
- Unidentified speaker (speaker_3): downgrade, although, you know, as you get a bigger revenue base, clearly company thirty percent's hard. So reducing twenty-five is sensible, and yet the market saw that as a big as a big negative. So it's been sold off very badly in the back of that sentiment. I think also it's seen as a um as a stock that could be disrupted by AI. So as AI comes through, maybe hotels can go direct or AI
- 10:58
- Unidentified speaker (speaker_3): search can can find hotels without using intermediaries. I think both those are overplayed and and they actually have a partnership with Muse, you know, Meta's Muse, which is an agentic AI. So I think they'll be part of the solution, not the problem, if you like. It's now trading on very low multiples of revenue. Obviously, it's going through profitability, so multiples of EBIT
- 11:14
- Unidentified speaker (UNKNOWN): and
- 11:14
- Unidentified speaker (speaker_3): EBITDAR. EBITDA are still pretty high, but they they quickly reduce as the stock continues to grow, assuming it's um you can turn AI into an ally rather than a threat.
- 11:23
- Unidentified speaker (speaker_1): Yeah, of course. Okay. Matt, close us out.
- 11:25
- Unidentified speaker (UNKNOWN): Yes, yeah. For us it's
- 11:26
- Unidentified speaker (speaker_2): Cochlear. So really a similar story to Ramsey. It's a it's a stock that, you know, we owned once again back in the early days of the fund. It moved into the leaders. Um it's come back, and um they are the you know the leader leader globally. globally in terms of cochlear implants, in fact, the inventor of it. And last year they essentially just ran into a perfect storm. So especially in the
- 11:46
- Unidentified speaker (speaker_2): second half. So you had reimbursement issues in the US, in the UK, they had capacity issues.
- 11:54
- Unidentified speaker (speaker_2): There was industrial action in Europe, which probably happens all the time, I'm right? And um, yeah, so it really like um you know it really hit their profit quite hard. So look looking into this year, um, unlike you know Ramsey, where we're starting to see the earnings growth coming through, I mean, all we're really looking for this year is just a a stabilization because we can beyond that we can see some tailwinds
- 12:13
- Unidentified speaker (speaker_2): coming through. So the first of those is they've they've introduced a new implant um called Nexa. And they actually haven't they've introduced the implant but not some of the software that goes with it. So over time we think, you know, as that proves itself, they'll be they'll be able to get better reimbursement from that. And then the other one, which is really interesting, and this is this is more medium term, is that
- 12:33
- Unidentified speaker (speaker_2): we're starting to see the emergence of um fully implantable devices. So that that will come out in a few years. But I just speaking from experience, my my mum's actually a cochlear implant recipient. And there can actually, there's a real stigma, you know, for people getting them because you know it means you have to, you know, where wear you a know. external device as well as a microphone.
- 12:53
- Unidentified speaker (speaker_2): And um that that can be a barrier to people coming on board. So when it finally comes through and it, much like hearing aid, you can't see it, we think that will actually expand the market, you know, quite, quite significantly down the track. So yeah, for us, you you don't get many chances to buy quality stocks, you know, that have are f fallen formed by, you know, essentially sort of a half. So that that's the opportunity.
- 13:13
- Unidentified speaker (speaker_1): Thank you so much for watching by Buy whole Hold self. Sell. Thank you to our guests and make sure to subscribe to our channel for more buy hold sell episodes
More from Buy Hold Sell, by Livewire Markets
Buy Hold Sell: 5 ASX stocks flying too close to the sun
Episode discussion: Panel discusses valuation discipline and rates five ASX stocks: Codan, NextGen Energy, Life360, Monadelphous, and Hub24.
Speakers’ claims: Speakers outline a bottom-up valuation methodology based on five-year cash flow forecasts, selling when prices exceed intrinsic value. They analyze Codan (ASX:CDN), noting strong earnings growth from metal detection and communications, with mixed ratings due to cyclical risks. NextGen Energy (ASX:NXE) is highlighted as a low-cost uranium project benefiting from baseload power demand, receiving buy/hold ratings. Life360 (ASX:L36) is discussed regarding its user base and advertising expansion, with divergent views on valuation and churn. Monadelphous (ASX:MDP) is rated a hold due to full valuation despite operational excellence. Hub24 (ASX:HUB) is analyzed for its wealth platform migration and budget impacts, with mixed ratings based on historical multiples versus peer comparisons.
Buy Hold Sell: 6 ASX stocks built to handle tough conditions
Episode discussion: Hosts debate defensive ASX stocks including Coles, Telstra, and HMC Capital amid tough market conditions.
Speakers’ claims: Luke Larative and Nick Pashus discuss their investment theses for six ASX-listed companies, focusing on valuation and defensive characteristics. Larative recommends selling Coles and Telstra due to high valuations and competitive threats, while buying HMC Capital, NextDC, and holding Pro Medicus. Pashus takes opposing views, recommending buying Coles for its fixed-cost leverage, holding Telstra despite satellite risks, and buying Pro Medicus and Eliza Gold. The hosts emphasize the importance of valuation discipline and margin of safety in navigating uncertain economic conditions.